Table 6 Clinical efficacy studies: Rhinosinusitis
From: Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections
First Author (Year) | Objectives of study | Intervention | Results |
|---|---|---|---|
Wawrose (1992) | To evaluate the role of guaifenesin in decreasing symptoms of postnasal drainage and nasal congestion in HIV+ patients with chronic rhinosinusitis | Double-blind parallel-group study: 1200 mg guaifenesin vs placebo 2× daily for 3 weeks | Significantly less nasal congestion and thinner postnasal drainage reported after 3 weeks of treatment with guaifenesin vs placebo (p < 0.05) |
Rosen (2005) | To evaluate the effect of guaifenesin on mucociliary clearance time (MCT) and sinonasal symptoms in HIV+ patients | Randomized double-blind parallel-group study: 1200 mg guaifenesin vs placebo 2× daily for 3 weeks | Significant improvement in sinonasal symptom survey (SNOT-16) score in HIV+ patients treated with guaifenesin vs placebo (p < 0.05) |